Weight-Loss drug may boost heart procedure success
NCT ID NCT07389941
First seen Feb 05, 2026 · Last updated May 20, 2026 · Updated 16 times
Summary
This study tests whether taking semaglutide (a diabetes/weight-loss drug) before a standard heart procedure called catheter ablation helps prevent atrial fibrillation from coming back. About 240 adults with obesity and symptomatic AF will receive either semaglutide or standard care before their first ablation. The main goal is to see if more people stay free of irregular heart rhythms one year after the procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.